Inducing Immune Tolerance in Organ Transplant Recipients
Talaris Therapeutics is developing transformative cell therapies with the potential to eliminate the burden of chronic immunosuppression for organ transplant recipients, as well as induce durable remissions in patients with severe auto-immune and immune-mediated disorders.
“For developmental studies, along with clinical manufacturing, we were looking for a faster, more reliable cell counter that performed better than our current method. After a side-by-side comparison, the NucleoCounter® NC-202™ provided better, more consistent counts of our product. This has drastically reduced our cell counting time and reduced the variation between each count.”
“The NC-202™ is a more suitable option for cell counts in a GMP environment which provided us the opportunity to perform cell counts within the GMP environment. This change in cell counting devices has greatly improved the time it takes to process our product while also increasing the consistency of the cell counts which affects downstream read outs.”
Alicia Wallis, Principal Scientist, Process Development
Learn more about Talaris Therapeutics